Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome
NCT06186648
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Richter Syndrome
Interventions
DRUG:
Glofitamab + Obinutuzumab
Sponsor
French Innovative Leukemia Organisation
Collaborators
[object Object]